TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06773299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAT+HEALTH curriculum - Nigeria
Description: This intervention is an adaption of the PAT Curriculum and the HEALTH intervention specifically tailored for the Nigerian context.
Study: NCT06771609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebry single antibody + VEX metronomic chemotherapy + radiotherapy
Description: 1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: debry single antibody + VEX metronomic chemotherapy
Description: 1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
Study: NCT06772857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is a drug used to manage blood glucose levels. It improves insulin sensitivity and reduces glucose production in the liver. This regimen will be provided to all study groups (A, B, and C) in combination with the respective interventions described for each group. Participants are instructed not to change their physical activity during the study.
Study: NCT05613530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAX NEONAT
Description: Participants use a digital, hand-held, cognitive aid (a mobile application named MAX NEONAT) and the ILCOR 2020 algorithm poster.~This group consists of a resident in pediatrics + 2 midwifes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: no cognitive aid but poster/paper only
Study: NCT05261620

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red wine
Description: Subjects in the intervention arm (SoC+WISE) will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men. Total polyphenolic contents and antioxidant activity (Folin-Ciocalteu method with calibration curve in gallic acid), antioxidant/radical scavenger capacity \[DPPH (2,2-diphenyl-1-picrylhydrazyl) test\] and phenolic profiles \[HPLC (High Performance Liquid Chromatography)/DAD (diode-array detector) /ESI-MS (Electrospray Ionisation Mass Spectrometry) analysis\] will be performed for wine selection for the clinical trial.
Study: NCT05802953

Intervention type: OTHER
Intervention: Physical assessments
Description: Physical assessments include the presence of joint sounds (yes/no), Fonseca Anamnestic Questionnaire, tenderness/pressure pain threshold rating, muscle strengths assessments, temporomandibular joint and cervical region range of motion measurements, and pain.

Intervention type: OTHER
Intervention: Questionnaire
Description: General Health Questionnaire-28 and SF-36 will be apply.
Study: NCT06523413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game activity
Description: A game determined by the researcher will be played with the patients in the patient room.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stres Ball
Description: Patients will use the stress ball for 15 minutes.
Study: NCT05536271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate
Description: antihypertensive medicine prescribed for acute coronary syndrome patients
Study: NCT06157788

Intervention type: DIAGNOSTIC_TEST
Intervention: functional Magnetic Resonance Imaging and clinical assessment
Description: * fMRI task: In the active condition, video cues were utilized (lasting 10s) depicting everyday activities that trigger shoulder apprehension. Control videos were created to match the previous content, except for the absence of cues inducing shoulder apprehension. Following each video, a visual analog scale appeared for a duration of 2.5s, and participant were asked to rate the level of perceived apprehension, using an MRI-compatible response box. The rating scale consisted of nine steps, ranging from no apprehension to high apprehension. After providing their rating, participants had a rest period during which a fixation cross was displayed visually for 17.5s. Apprehension and control videos were shown in a pseudo-randomized fashion.~* General Linear Model Analysis of Task-Related Activation~* TICA Analysis of Functional Connectivity~* White Matter TBSS of DTI Data~* Voxel-based morphometry analysis of T1 images

Intervention type: DIAGNOSTIC_TEST
Intervention: functional Magnetic Resonance Imaging and clinical assessment
Description: * fMRI task: In the active condition, video cues were utilized (lasting 10s) depicting everyday activities that trigger shoulder apprehension. Control videos were created to match the previous content, except for the absence of cues inducing shoulder apprehension. Following each video, a visual analog scale appeared for a duration of 2.5s, and participant were asked to rate the level of perceived apprehension, using an MRI-compatible response box. The rating scale consisted of nine steps, ranging from no apprehension to high apprehension. After providing their rating, participants had a rest period during which a fixation cross was displayed visually for 17.5s. Apprehension and control videos were shown in a pseudo-randomized fashion.~* General Linear Model Analysis of Task-Related Activation~* TICA Analysis of Functional Connectivity~* White Matter TBSS of DTI Data~* Voxel-based morphometry analysis of T1 images
Study: NCT05331534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye-tracking assisted attention control training (ACTo)
Description: ACT is made of 8 sessions of a Dot-Probe Task (DPT). The DPT is a computerized task in which two visual stimuli (one emotional stimulus and one neutral stimulus) are displayed simultaneously on the left and right side of the screen. AB towards or away from emotional stimuli is respectively inferred by faster or slower responses to detect a probe replacing an emotional stimulus than a probe replacing a neutral stimulus. In the ACT therapy, the probe replaces the negative and neutral stimuli with equal frequency.~ACTo will combine ACT with eye tracking methodology, allowing to directly record eye movements of the participants during the task. At each trial, images will be displayed for 2s and the negative image will be replaced by the neutral image (and vice versa) if the patient continues to explore the negative image beyond the first fixation, in order to block any additional attentional engagement.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention control training (ACT)
Description: Patients will benefit from the ACT as described above; at each trial, images will remain on screen for 2s.
Study: NCT06471764

Intervention type: DEVICE
Intervention: FX+ and 12-Lead ECG Recording
Description: While lying down, subjects will wear the FX+, a chest strap device which will measure cardiac electrical activity to generate a continuous heart rate measurement. Simultaneously, electrodes for the 12-Lead ECG will be placed on the chest and arms/legs to record the electrical activity. Two 30-second recordings from the FX+ will be taken simultaneously with the 12-lead ECG with no more than a 3-minute interval between the two recordings.
Study: NCT04676737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141)
Description: TTHX1114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141)
Description: TTHX1114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141)
Description: TTHX1114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141)
Description: TTHX1114
Study: NCT05376085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5215 Tab
Description: single oral administration of 1 tablet of DA-5215 Tab with 150mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5215 Tab
Description: single oral administration of 1 tablet of DA-5215 Tab with 150mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5215-R Tab
Description: single oral administration of 1 tablet of DA-5215-R Tab with 150mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5215-R Tab
Description: single oral administration of 1 tablet of DA-5215-R Tab with 150mL water
Study: NCT06536400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK42360
Description: Oral administration, QD
Study: NCT05575050

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Procedure
Description: Interventions included 2 variants of oral hygienic procedures. One was extended of teeth brushing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Procedure
Description: Interventions included 2 variants of oral hygienic procedures. One was extended of teeth brushing.
Study: NCT05366504

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: LiST + PRP intracorporeal injection
Description: 12 LiST sessions (2 sessions per week) plus PRP (2 intracorporeal injections 3 weeks apart, after the 1st and the 7th LiST sessions) ( 30 patients).

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: LiST + Placebo(normal saline intracorporeal injection)
Description: All subjects of this group will receive 12 sessions (V3-V14) of LiST with session frequency 2/week and 2 normal saline injections with 3 weeks treatment interval (V3 and V9), 10 ml of normal saline will be injected at each session.
Study: NCT06536400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK42360
Description: Oral administration, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK42360
Description: Oral administration, QD
Study: NCT06772857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is a drug used to manage blood glucose levels. It improves insulin sensitivity and reduces glucose production in the liver. This regimen will be provided to all study groups (A, B, and C) in combination with the respective interventions described for each group. Participants are instructed not to change their physical activity during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is a drug used to manage blood glucose levels. It improves insulin sensitivity and reduces glucose production in the liver. This regimen will be provided to all study groups (A, B, and C) in combination with the respective interventions described for each group. Participants are instructed not to change their physical activity during the study.
Study: NCT01184950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trainer Curriculum
Study: NCT06772584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin Acetate 0.2 mg Tablets
Description: 3 groups of patients one received only desmopressin and group ginkobiloba ablnd group for both

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin Acetate 0.2 mg Tablets
Description: 3 groups of patients one received only desmopressin and group ginkobiloba ablnd group for both

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgobiloba
Description: Group s take it as treatment of deep sleep in nectornal enuresis
Study: NCT05878652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed knee extender device
Description: Participants will receive the standard of prehabilitation education at Sanford as well as a 3D printed knee extension device with sealed water bottles and a home prehabilitation program designed to be used with the 3D printed knee extension device.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Prehabilitation Education
Description: Participants in the control group will receive the standard prehabilitation education at Sanford and provided exercises to do at home.
Study: NCT05069584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: patient must have a biopsy for his prostate cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: patient must have a biopsy for his prostate cancer
Study: NCT06189937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive Behavioral Therapy (CA-CBT)
Description: In this study, an 8- session (90 to 120 minutes) group version of the transdiagnostic intervention CA-CBT tailored for earthquake survivors will be applied.~Contents of the sessions are:~1. Education on psychological trauma and its treatment, and basics of emotion regulation techniques~2. Education on anxiety and depressive disorders and their treatment~3. Muscle relaxation and stretching exercises~4. Education about depressive and grief-related disorders and disturbing memories protocol~5. Interoceptive exposure: head rotation and hyperventilation~6. Anxiety, worry, and stress~7. Anger and anger protocol; breathing exercises~8. Somatic complaints, sleep disturbance, and closing~There will be one facilitator and one co-facilitator. Groups will consist of 12-13 participants.
Study: NCT05358379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC140
Description: CYC140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC140
Description: CYC140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Study: NCT05818657

Intervention type: BIOLOGICAL
Intervention: levels of CKD markers, Oral health status, apical periodontitis
Description: To observe levels of CKD markers :Levels of serum keratinise ,urea, eGFR, and assessment of Oral health status, apical periodontitis

Intervention type: BIOLOGICAL
Intervention: systemic inflammatory marker, Oral health status, apical periodontitis
Description: estimation of hs-CRP levels, and assessment of Oral health status, apical periodontitis
Study: NCT05964283

Intervention type: OTHER
Intervention: Questionnaire
Description: This questionnaire consists of (five) main parts. The first part is about personal information, the second part is about fluid administration in various settings (emergency room, operating room, and intensive care unit), the third part is about fluid administration behaviors, the fourth part is about workplace location, and the fifth part is about a case study. Filling out this questionnaire will take approximately 60 minutes of your time.

Intervention type: OTHER
Intervention: Questionnaire
Description: This questionnaire consists of (five) main parts. The first part is about personal information, the second part is about fluid administration in various settings (emergency room, operating room, and intensive care unit), the third part is about fluid administration behaviors, the fourth part is about workplace location, and the fifth part is about a case study. Filling out this questionnaire will take approximately 60 minutes of your time.
Study: NCT05541536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation meeting
Description: Study team member will approach mothers \< 24 hrs (up to 5 min prior) of CRC approach for NRN trial. During the consultation meeting (5 minutes), the study team member will review the pamphlet and answer any questions. Visits will ideally occur in person. If the mother is not at bedside, 1 attempt will be made to reach the mother by phone in which case the pamphlet will be forwarded by mail.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pamphlet
Description: Study team member will distribute pamphlet to beside nurse to give to mother. The pamphlet provides information about Learning Health Care (LHC) and clinical research.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Study participants will not receive the general information pamphlet or consultation.
Study: NCT04572152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK119
Description: Subjects will receive AK119 by intravenous administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: On the same day subjects will receive AK104 by intravenous administration.
Study: NCT05827198

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-sugar candies compared to regular sugar candies
Description: Acute intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-sugar candies compared to regular sugar candies
Description: Acute intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-sugar candies compared to regular sugar candies
Description: Acute intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-sugar candies compared to regular sugar candies
Description: Acute intake
Study: NCT05884749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer to Community (P2C) Model
Description: The P2C model is an outreach model including peer support, occupational therapy and social work aimed at facilitating community integration through relationship building and meaningful activity engagement for individuals living with concurrent disorders following homelessness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual (UC)
Description: Participants in this group will receive care available typically in the community
Study: NCT04608903

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-sulforaphane 1%
Description: Administration of 4g L-sulforaphane per day, for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Administration of 4g corn starch colored with chlorophyll, per day, for 2 months
Study: NCT05031741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Leader Model
Description: Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liason via text messages throughout the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Leader Model
Description: Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liason via text messages throughout the study.
Study: NCT06772584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgobiloba
Description: Group s take it as treatment of deep sleep in nectornal enuresis
Study: NCT06772805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral Tablet
Study: NCT06496672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified long arm cast
Description: A shorter cast that frees the wrist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional long arm cast
Description: Current standard of care where the cast extends up to the palmar bar
Study: NCT04881123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER150
Description: Dosage Level(s): 30 mg (1 capsule of 15 mg twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Level(s): Matched placebo (1 capsule twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
Study: NCT05274230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Wearable
Description: Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear everyday. They will be asked to continue to wear the device until all study data is collected.
Study: NCT06309056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalStim
Description: VitalStim is a device that provides neuromuscular electrical stimulation. It will be applied on muscles related to swallowing to stimulate muscle contraction.
Study: NCT05599490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
Study: NCT05066789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Type of stent
Description: 1:1 randomization to biodegradable polymer DES (Orsiro Mission) and polymer-free DCS (Biofreedom)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Type of stent
Description: 1:1 randomization to biodegradable polymer DES (Orsiro Mission) and polymer-free DCS (Biofreedom)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duration of DAPT
Description: 1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duration of DAPT
Description: 1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)
Study: NCT06348108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Given subcutaneously (SQ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Given subcutaneously (SQ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Given subcutaneously (SQ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Given subcutaneously (SQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy